Identification of differentially methylated CpG islands in prostate cancer

International Journal of Cancer

Volumn 112, Issue 5, 2004, Pages 840-845

  Yamada, Yasushi ^a   Toyota, Minoru ^b   Hirokawa, Yoshifumi ^a   Suzuki, Hiroyoshi ^c   Takagi, Akimitsu ^a,d   Matsuzaki, Takeshi ^d   Sugimura, Yoshiki ^a   Yatani, Ryuichi ^a   Shiraishi, Taizo ^a   Watanabe, Masatoshi ^a,e  

^a MIE UNIVERSITY   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^e YOKOHAMA NATIONAL UNIVERSITY   (Japan)

Author keywords

MCA RDA; Methylation; Prostate cancer

Indexed keywords

BISULFITE; DNA FRAGMENT; MESSENGER RNA; NEUROTROPHIN RECEPTOR; PROTEIN; PROTOCADHERIN FLAMINGO1 PROTEIN; TRANSFERASE INHIBITOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DISEASE COURSE; DNA METHYLATION; FRAGMENTATION REACTION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROSTATE CANCER; PROTEIN EXPRESSION; SAMPLING; SEQUENCE ANALYSIS; TUMOR GROWTH;

ANIMALS; CPG ISLANDS; DNA METHYLATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 7244261706     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20335     Document Type: Article

References (23)

1. Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437-43.
2. Ozen M, Pathak S. Genetic alterations in human prostate cancer: a review of current literature. Anticancer Res 2000;20:1905-12.
3. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
4. Bird AP, Wolffe AP. Methylation-induced repression: belts, braces, and chromatin. Cell 1999;99:451-4.
5. Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Ito H, Yatani R, Shiraishi T. The role of epigenetic modifications in retinoic acid receptor β2 gene expression in human prostate cancers. Lab Invest 2001;81:1049-57.
6. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, Nelson WG. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-7.
7. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinoma. Cancer Res 1995;55:5195-9.
8. Kuzmin J, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, Vocke CD, Duh FM, Zabarovsky E, Minna JD, Rhim JS, Emmert BMR, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002;62:3498-502.
9. Maruyama R, Toyooka S, Toyooka KM, Virmani AK, Zochbauer-Muller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-9.
10. Kawai J, Hirotsune S, Hirose K, Fushiki S, Watanabe S, Hayashizaki Y. Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method. Nucleic Acids Res 1993;21:5604-8.
11. Toyota M, Ho C, Ahuja N, Jair KW, Li Q, Ohe-toyota M, Baylin SB, Issa JJ. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res 1999;59:2307-12.
12. Huang TH, Perry MR, Laux DE. Methylarion profiling of CpG islands in human breast cancer cells. Hum Mol Genet 1999;8:459-70.
13. Ueki T, Toyota M, Skinner H, Walter KM, Yeo CJ, Issa JJ, Hruban RH, Goggins M. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 2001; 61:8540-6.
14. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molly PL, Pail CL. A genomic sequencing protocol that yields a positive display of 5-methylsitosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827-31.
15. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylatton assay. Nucleic Acids Res 1997;25:2532-4.
16. Gardiner GM, Frommer M. CpG islands invertebrate genomes. J Mol Biol 1987;196:261-82.
17. Stotlov P, Castren E, Stamm S. Analysts of the human TrkB gene genomic organization reveals novel TrkB isoforms, unusual gene length, and splicing mechanism. Biochem Biophys Res Commun 2002;290:1054-65.
18. Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol 1994;25:1386-403.
19. Thoenen H. Neurotrophins and neuronal plasticity. Science 1995;270: 593-8.
20. Rubin JB, Segal RA. Growth, survival and migration: the Trk to cancer. Cancer Treat Res 2003;115:1-18.
21. Dionne CA, Camoratto AM, Jani JP, Emerson E, Naff JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 1998; 4:1887-98.
22. Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki S, Dionne CA, Isaacs JT. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clin Cancer Res 200;7:2237-45.
23. McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD, Ball DW, Baylin SB, Nelkin BD. Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci USA 1999;96:4540-5.